CLINICAL RESEARCH: INTERVENTIONAL CARDIOLOGY
Treatment of multivessel coronary artery disease with sirolimus-eluting stent implantation: immediate and mid-term results
Dejan Orlic, MD*,
Erminio Bonizzoni, PhD ,
Goran Stankovic, MD*,
Flavio Airoldi, MD ,
Alaide Chieffo, MD,
Nicola Corvaja, MD*,
Giuseppe Sangiorgi, MD*,
Massimo Ferraro, RN*,
Carlo Briguori, MD,
Matteo Montorfano, MD,
Mauro Carlino, MD and
Antonio Colombo, MD, FACC*,*
* EMO, Centro Cuore Columbus Hospital, Milan, Italy
San Raffaele Hospital, Milan, Italy
Institute of Medical Statistics and Biometry, University of Milan, Milan, Italy
Manuscript received June 16, 2003;
revised manuscript received October 17, 2003,
accepted October 20, 2003.
* Reprint requests and correspondence: Dr. Antonio Colombo, EMO Centro Cuore Columbus, Via Buonarroti 48, Milan, Italy.
info{at}emocolumbus.it
OBJECTIVES: This study evaluated clinical outcome after multivessel stenting with sirolimus-eluting stents (SES) in unselected lesions.
BACKGROUND: Safety and effectiveness of multivessel SES implantation is currently unknown.
METHODS: Major adverse cardiac events (MACE) (death, myocardial infarction [MI], and repeat revascularization) were analyzed at 30 days and at 6 months after multivessel SES implantation.
RESULTS: In 155 consecutive patients, 573 SES were implanted in 3.3 ± 1.3 lesions per patient. At 30 days, the cumulative MACE rate was 10.3%: 7.1% patients developed a non–Q-wave MI, 1.9% developed a Q-wave MI, 0.6% died for non-cardiac reasons, and 0.6% had a repeat revascularization. Clinical follow-up was obtained in all 112 eligible patients treated for 359 lesions at a mean time of 6.5 ± 2.2 months. The cumulative MACE rate was 22.3%: 3 (2.7%) deaths (1 for cardiac reasons), 4 (3.6%) MIs, target lesion revascularization (TLR) in 16 (14.3%) patients with 24 (6.7%) lesions. Target vessel revascularization was required in 18 (16.1%) patients due to TLR of lesions treated with SES or to disease progression (1.8% of patients). Cox regression analysis revealed total stent length per patient as the most powerful independent predictor of MACE. Overall stent thrombosis occurred in three (1.9%) patients.
CONCLUSIONS: Multivessel SES implantation can be safely performed on patients with complex coronary artery disease. The need for revascularization increases because of the cumulative effect of TLR on patients with multiple lesions.
|
Abbreviations and Acronyms
| | BMS | = bare metal stent | | CABG | = coronary artery bypass grafting | | CK | = creatine kinase | | MACE | = major adverse cardiac events | | MI | = myocardial infarction | | PCI | = percutaneous coronary intervention | | PTCA | = percutaneous transluminal coronary angioplasty | | SES | = sirolimus-eluting stent | | SIRIUS | = U.S. Multicenter, Randomized, Double-Blind Study of the Sirolimus- Eluting Stent in De Novo Native Coronary Lesions | | TLR | = target lesion revascularization | | TVR | = target vessel revascularization |
|
This article has been cited by other articles:
|
|
|
|
 
A. S.P. Sharp, A. Latib, A. Ielasi, C. Larosa, C. Godino, M. Saolini, V. Magni, R. T. Gerber, M. Montorfano, M. Carlino, et al.
Long-Term Follow-Up on a Large Cohort of "Full-Metal Jacket" Percutaneous Coronary Intervention Procedures
Circ Cardiovasc Interv,
October 1, 2009;
2(5):
416 - 422.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Valenti, A. Migliorini, U. Signorini, R. Vergara, G. Parodi, N. Carrabba, G. Cerisano, and D. Antoniucci
Impact of complete revascularization with percutaneous coronary intervention on survival in patients with at least one chronic total occlusion
Eur. Heart J.,
October 1, 2008;
29(19):
2336 - 2342.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. H. Yang, H.-C. Gwon, S. J. Cho, J. Y. Hahn, J.-H. Choi, S. H. Choi, Y. T. Lee, S. H. Lee, K. P. Hong, and J. E. Park
Comparison of Coronary Artery Bypass Grafting With Drug-Eluting Stent Implantation for the Treatment of Multivessel Coronary Artery Disease
Ann. Thorac. Surg.,
January 1, 2008;
85(1):
65 - 70.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Colombo and A. Chieffo
Drug-Eluting Stent Update 2007: Part III: Technique and Unapproved/Unsettled Indications (Left Main, Bifurcations, Chronic Total Occlusions, Small Vessels and Long Lesions, Saphenous Vein Grafts, Acute Myocardial Infarctions, and Multivessel Disease)
Circulation,
September 18, 2007;
116(12):
1424 - 1432.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Cosgrave, G. Melzi, S. Corbett, G. G.L. Biondi-Zoccai, P. Agostoni, R. Babic, F. Airoldi, A. Chieffo, G. M. Sangiorgi, M. Montorfano, et al.
Comparable Clinical Outcomes With Paclitaxel- and Sirolimus-Eluting Stents in Unrestricted Contemporary Practice
J. Am. Coll. Cardiol.,
June 19, 2007;
49(24):
2320 - 2328.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Beohar, C. J. Davidson, K. E. Kip, L. Goodreau, H. A. Vlachos, S. N. Meyers, K. H. Benzuly, J. D. Flaherty, M. J. Ricciardi, C. L. Bennett, et al.
Outcomes and Complications Associated With Off-Label and Untested Use of Drug-Eluting Stents
JAMA,
May 9, 2007;
297(18):
1992 - 2000.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Matsumoto, J. Shite, T. Shinke, H. Otake, Y. Tanino, D. Ogasawara, T. Sawada, O. L. Paredes, K.-i. Hirata, and M. Yokoyama
Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography
Eur. Heart J.,
April 2, 2007;
28(8):
961 - 967.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Tsuchida, A. Colombo, T. Lefevre, K. G. Oldroyd, V. Guetta, G. Guagliumi, W. von Scheidt, W. Ruzyllo, C. W. Hamm, M. Bressers, et al.
The clinical outcome of percutaneous treatment of bifurcation lesions in multivessel coronary artery disease with the sirolimus-eluting stent: insights from the Arterial Revascularization Therapies Study part II (ARTS II)
Eur. Heart J.,
February 2, 2007;
28(4):
433 - 442.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. J. Corbett, J. Cosgrave, G. Melzi, R. Babic, G. G.L. Biondi-Zoccai, C. Godino, N. Morici, F. Airoldi, I. Michev, M. Montorfano, et al.
Patterns of restenosis after drug-eluting stent implantation: insights from a contemporary and comparative analysis of sirolimus- and paclitaxel-eluting stents
Eur. Heart J.,
October 1, 2006;
27(19):
2330 - 2337.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. W. Stone, S. G. Ellis, L. Cannon, J. T. Mann, J. D. Greenberg, D. Spriggs, C. D. O'Shaughnessy, S. DeMaio, P. Hall, J. J. Popma, et al.
Comparison of a Polymer-Based Paclitaxel-Eluting Stent With a Bare Metal Stent in Patients With Complex Coronary Artery Disease: A Randomized Controlled Trial
JAMA,
September 14, 2005;
294(10):
1215 - 1223.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Ge, I. Iakovou, J. Cosgrave, A. Chieffo, M. Montorfano, I. Michev, F. Airoldi, M. Carlino, G. Melzi, G. M. Sangiorgi, et al.
Immediate and mid-term outcomes of sirolimus-eluting stent implantation for chronic total occlusions
Eur. Heart J.,
June 1, 2005;
26(11):
1056 - 1062.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. W. O'Neill, S. R. Dixon, and C. L. Grines
The year in interventional cardiology
J. Am. Coll. Cardiol.,
April 5, 2005;
45(7):
1117 - 1134.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. N. DeMaria, O. Ben-Yehuda, D. Berman, G. K. Feld, B. H. Greenberg, J. D. Knoke, K. U. Knowlton, W. Y.W. Lew, J. Narula, D. Sahn, et al.
Highlights of the year in JACC 2004
J. Am. Coll. Cardiol.,
January 4, 2005;
45(1):
137 - 153.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. M. Biasucci and G. G.L. Biondi-Zoccai
Preprocedural C-Reactive Protein for Risk Prediction Before Percutaneous Coronary Intervention (PCI): A European Perspective
Clin. Chem.,
September 1, 2004;
50(9):
1492 - 1494.
[Full Text]
[PDF]
|
|
|
|
